Targets › HTR1D
7 programs from 5 companies in 12 trials: 5 Phase 1, 3 Phase 2, 2 Phase 3, 2 Phase 4; Psychiatry, Neurology, Other; next expected readout Dec 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. (UniProt, P28221)
Open in Phaseline: the race on HTR1D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zogenix | Fenfluramine Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile Spasm | Nov 2027 |
| UCB BIOSCIENCES | fenfluramine hydrochloride Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | Rett Syndrome | Feb 2029 |
| University Hospital, Basel, Switzerland | Lysergic Acid Diethylamide Tartrate (LSD) Serotonin receptor agonist (5-HT1B/1D/7) | HTR1B, HTR1D | Phase 2 | Palliative Care; Cluster Headache | Sep 2027 |
| Yale University | Dimethyltryptamine (DMT) Serotonin 5-HT receptor agonist; endogenous psychedelic compound | HTR1A, HTR1B, HTR1D, HTR2A | Phase 1 | Major Depressive Disorder; Alcohol Use Disorder (AUD) | Dec 2026 |
| Technophage | Eletriptan Hydrobromide Serotonin 1f (5-HT1f) receptor agonist; Serotonin 1b (5-HT1b) receptor agonist; Serotonin 1d (5-HT1d) receptor agonist | HTR1F, HTR1B, HTR1D | Phase 1 | Acute Spinal Cord Injury (SCI) | Dec 2026 |
| University Hospital, Basel, Switzerland | DMT 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
| University Hospital, Basel, Switzerland | LSD 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
Healthy (2) Rett Syndrome (1) Palliative Care (1) Cluster Headache (1) CDKL5 Deficiency Disorder (1) Dravet Syndrome (DS) (1) Dravet Syndrome (1) Infantile Spasm (1) Major Depressive Disorder (1) Alcohol Use Disorder (AUD) (1) Acute Spinal Cord Injury (SCI) (1)
small molecule (7)
University Hospital, Basel, Switzerland (3) UCB BIOSCIENCES (1) Zogenix (1) Yale University (1) Technophage (1)
HTR1B (5) HTR1A (3) HTR2C (2) SIGMAR1 (2) HTR5A (2) HTR7 (2) HTR2A (1) HTR1F (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.